Sillett R W, Dash C H, McNicol M W
Eur J Clin Pharmacol. 1976 Feb 6;9(4):281-4. doi: 10.1007/BF00561661.
The responses of twelve patients with chronic asthma to salmefamol 1 mg and 2 mg, taken orally, were compared in a double-blind cross-over study. Both produced a rise of 40-50% in PEFR and FEV1. Statistically significant improvements were maintained for three to four hours, and 20% improvements for four to six hours. There was no significantly different effect on ventilatory capacity between the two doses. After the 2 mg dose there was a statistically significant fall in diastolic blood pressure at 1 and 1 1/2 hours. Four patients experienced tremor and this was the only side-effect noted. The possible reasons for failure to demonstrate a greater effect with the higher dose are discussed.
在一项双盲交叉研究中，比较了12例慢性哮喘患者口服1毫克和2毫克沙美特罗的反应。两者均使呼气峰流速（PEFR）和第一秒用力呼气容积（FEV1）提高了40%-50%。统计学上显著的改善维持了三到四个小时，20%的改善维持了四到六个小时。两种剂量对通气能力的影响没有显著差异。服用2毫克剂量后，1小时和1个半小时时舒张压有统计学上的显著下降。4名患者出现震颤，这是唯一观察到的副作用。讨论了未能证明高剂量有更大效果的可能原因。
